BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Denali Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Denali Therapeutics's drugs run\,
  from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06602193-1609@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BIIB122 / DNL151 (LRRK2 inhibitor): Phase 2 readout est. (NCT066021
 93)
DESCRIPTION:BIIB122 / DNL151 (LRRK2 inhibitor)\, phase 2\, Parkinson's Dise
 ase.\nStudy: Safety and Pharmacodynamic Effects of BIIB122 in Participants
  With LRRK2-Associated Parkinson's Disease (LRRK2-PD)\nEstimated primary c
 ompletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/biib122-dnl151-lrrk2-inhibitor#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06602193
URL:https://assetmemo.bio/drug/biib122-dnl151-lrrk2-inhibitor#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06075537-10788@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT06075537)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: An Extension Study of the Long-Term Safety\, Tolerabilit
 y\, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopo
 lysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-00
 07\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06075537
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05371613-10788@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Avlayah (Tividenofusp alfa): Phase 2/3 readout est. (NCT05371613)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 2/3\, Mucopolysaccharidosis
  Type II.\nStudy: A Study to Determine the Efficacy and Safety of Tivideno
 fusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participant
 s With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis 
 Type II (nnMPS II)\nEstimated primary completion: December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05371613
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04251026-10788@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Avlayah (Tividenofusp alfa): Phase 1/2 readout est. (NCT04251026)
DESCRIPTION:Avlayah (Tividenofusp alfa)\, phase 1/2.\nStudy: A Study of Tiv
 idenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome\nEs
 timated primary completion: February 2031. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04251026
URL:https://assetmemo.bio/drug/tividenofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06181136-10789@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:DNL126: Phase 1/2 readout est. (NCT06181136)
DESCRIPTION:DNL126\, phase 1/2\, Mucopolysaccharidosis Type IIIA.\nStudy: S
 tudy of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type I
 IIA (Sanfilippo Syndrome Type A)\nEstimated primary completion: July 2032.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/dnl126#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06181136
URL:https://assetmemo.bio/drug/dnl126#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
